Edition:
United States

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

140.68USD
18 Oct 2017
Change (% chg)

$-0.11 (-0.08%)
Prev Close
$140.79
Open
$140.79
Day's High
$141.57
Day's Low
$140.07
Volume
1,951,895
Avg. Vol
1,806,776
52-wk High
$141.57
52-wk Low
$109.32

Latest Key Developments (Source: Significant Developments)

Johnson & Johnson Q3 earnings per share $1.37
Tuesday, 17 Oct 2017 06:40am EDT 

Oct 17 (Reuters) - Johnson & Johnson ::Johnson & Johnson reports 2017 third-quarter results.Q3 earnings per share $1.37.Q3 sales $19.7 billion versus I/B/E/S view $19.28 billion.Q3 earnings per share view $1.80 -- Thomson Reuters I/B/E/S.Sees FY 2017 adjusted earnings per share $7.25 to $7.30.Q3 adjusted non-GAAP earnings per share $1.90 excluding items.Sees FY 2017 sales $76.1 billion to $76.5 billion.Qtrly ‍worldwide pharmaceutical sales of $9.7 billion for Q3 2017 represented an increase of 15.4% versus prior year​.Excluding net impact of acquisitions and divestitures, on operational basis, worldwide, domestic, international sales each increased 3.8% in quarter​.Worldwide medical devices sales of $6.6 billion for Q3 2017 represented an increase of 7.1% versus prior year​.Qtrly ‍worldwide consumer sales of $3.4 billion for Q3 2017 represented an increase of 2.9% versus prior year​.Qtrly worldwide Velcade sales $273‍​ million versus $290 million in Q2 2017.Qtrly worldwide Remicade sales $‍​1,647 million versus $1,530 million in Q2 2017.Qtrly worldwide Zytiga sales $669‍​ million versus $558 million in Q2 2017.Qtrly worldwide Invokana/Invokamet sales $265‍​ million versus $295 million in Q2.Third-quarter 2017 net earnings included after-tax intangible amortization expense of approximately $0.9 billion​.Third-quarter 2017 net earnings included charge for after-tax special items of approximately $0.5 billion​.  Full Article

Cerveau Technologies announces research collaboration agreement with Janssen Pharmaceuticals
Monday, 16 Oct 2017 02:50pm EDT 

Oct 16 (Reuters) - Cerveau Technologies Inc: :Says announced a research collaboration agreement with Janssen Pharmaceuticals Inc for use of F-18MK-6240​ ‍​.Says collaboration is focused on using F-18MK-6240 as a biomarker in Janssen neurodegenerative disease research studies​.Says parties will collaborate on using F-18MK-6240 to diagnose and evaluate new treatments for neurodegenerative diseases in humans​.  Full Article

Johnson & Johnson says FDA approves Stelara for adolescents with moderate to severe plaque psoriasis
Friday, 13 Oct 2017 04:20pm EDT 

Oct 13 (Reuters) - Johnson & Johnson -:Janssen announces U.S. FDA approval of Stelara® (ustekinumab) for the treatment of adolescents with moderate to severe plaque psoriasis.  Full Article

CHMP issues positive opinion on Janssen’s ZYTIGA
Friday, 13 Oct 2017 07:49am EDT 

Oct 13 (Reuters) - Janssen-Cilag International NV::CHMP issues a positive opinion on Janssen's Zytiga to include earlier stage prostate cancer patients​.  Full Article

Janssen submits NDA for Apalutamide(ARN-509) to FDA
Wednesday, 11 Oct 2017 08:44am EDT 

Oct 11 (Reuters) - Johnson & Johnson :Janssen submits new drug application to U.S. FDA for Apalutamide (ARN-509) to treat men with non-metastatic castration-resistant prostate cancer.Janssen Biotech Inc says submission of the NDA for apalutamide​ is based on Phase 3 data from pivotal ARN-509-003 (SPARTAN) clinical trial.  Full Article

Bayer keeps forecast for peak Xarelto annual sales
Friday, 6 Oct 2017 03:25am EDT 

Oct 6 (Reuters) - Bayer Ag :Says keeps forecast for peak Xarelto annual sales despite new study results‍​.  Full Article

J&J diabetes care company Animas to close operations and exit insulin pump market
Thursday, 5 Oct 2017 07:00am EDT 

Oct 5 (Reuters) - Johnson & Johnson : :‍Johnson & Johnson Diabetes Care Companies - Animas corp intends to discontinue manufacturing, sale of animas vibe and onetouch ping insulin pumps.‍Johnson & Johnson Diabetes Care Companies - Animas corp also intends to close operations and exit insulin pump business​.‍Johnson & Johnson Diabetes Care Companies - Animas selected Medtronic as partner to facilitate transition for patients, caregivers, healthcare providers​.‍Johnson & Johnson Diabetes Care Companies - patients using an Animas insulin pump will be offered option to transfer to a Medtronic pump​.‍Johnson & Johnson Diabetes Care Companies - Johnson & Johnson is continuing to evaluate potential strategic options for Lifescan Inc​.‍Johnson & Johnson Diabetes Care Companies - for patients, healthcare providers outside of U.S., Canada Animas to continue to sell pumps, operate as usual​.  Full Article

JNJ announces completion of Codman Neurosurgery divestiture to Integra Lifesciences
Monday, 2 Oct 2017 04:01pm EDT 

Oct 2 (Reuters) - Johnson & Johnson :Johnson & Johnson announces completion of Codman Neurosurgery divestiture to Integra Lifesciences Holding Corporation.  Full Article

Janssen submits supplemental new drug application to FDA
Monday, 2 Oct 2017 08:00am EDT 

Oct 2 (Reuters) - Johnson & Johnson :Janssen submits supplemental new drug application (SNDA) to U.S. FDA seeking new indication for INVOKANA (canagliflozin) to reduce the risk of Major Adverse Cardiovascular Events (MACE) based on landmark canvas program.Janssen Research & Development - supplemental new drug application also applies to INVOKANA's fixed-dose combinations, INVOKAMET and INVOKAMET XR.  Full Article

Janssen submits new drug application to FDA
Monday, 25 Sep 2017 08:00am EDT 

Sept 25 (Reuters) - Janssen Research & Development LLC :Janssen submits new drug application to U.S. Food And Drug Administration for the first darunavir-based single tablet regimen for the treatment of HIV-1.Janssen Research & Development - Janssen seeks approval for investigational regimen.  Full Article

Photo

Johnson & Johnson wins reversal of $72 million verdict over talc cancer risks

Johnson & Johnson on Tuesday won the reversal of a $72 million verdict in favor of the family of a woman whose death from ovarian cancer they claimed stemmed from her use of the company's talc-based products like Johnson's Baby Powder.